Ind-Swift Laboratories Ltd Competitors & Peer Comparison
Pharmaceuticals · Indian listed companies
Compare Ind-Swift Laboratories Ltd with 125 companies shown from the same industry classification, including Solara Active Pharma Sciences Ltd, Kwality Pharmaceuticals Ltd, Unichem Laboratories Ltd. These are industry peers; their products, customers and business models may differ.
Selected-company price and ratio data: . Peer reporting dates can differ. Stored figures, not live quotes.
Compare valuation, size and returns
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Ind-Swift Laboratories Ltd | 3,547 Cr. | 408 | 420/87.0 | 54.5 | 159 | 0.00 % | 4.86 % | 4.02 % | 10.0 |
| Solara Active Pharma Sciences Ltd | 3,583 Cr. | 736 | 774/422 | 839 | 346 | 0.00 % | 4.86 % | 0.13 % | 10.0 |
| Kwality Pharmaceuticals Ltd | 3,712 Cr. | 3,577 | 3,949/829 | 45.5 | 321 | 0.00 % | 23.9 % | 22.5 % | 10.0 |
| Unichem Laboratories Ltd | 3,773 Cr. | 536 | 687/278 | 30.9 | 386 | 0.00 % | 4.13 % | 3.17 % | 2.00 |
| Aarti Drugs Limited | 3,900 Cr. | 430 | 534/319 | 22.5 | 154 | 0.47 % | 11.7 % | 12.7 % | 10.0 |
| Advanced Enzyme Technologies Ltd | 3,167 Cr. | 283 | 420/252 | 20.1 | 146 | 1.89 % | 14.0 % | 10.2 % | 2.00 |
| Gufic BioSciences Ltd | 4,224 Cr. | 420 | 468/268 | 57.4 | 66.2 | 0.02 % | 12.2 % | 9.98 % | 1.00 |
| SMS Pharmaceuticals Ltd | 4,329 Cr. | 462 | 494/240 | 47.8 | 85.9 | 0.09 % | 12.9 % | 11.9 % | 1.00 |
| Dishman Carbogen Amcis Ltd | 2,585 Cr. | 164 | 307/128 | 142 | 426 | 0.00 % | 3.14 % | 1.58 % | 2.00 |
| Hikal Ltd | 2,570 Cr. | 209 | 261/146 | 60.6 | 97.2 | 0.29 % | 3.50 % | 2.21 % | 2.00 |
| Zota Health Care Ltd | 4,579 Cr. | 1,322 | 1,740/1,022 | 200 | 0.08 % | 8.47 % | 15.0 % | 10.0 | |
| Indoco Remedies Ltd | 2,304 Cr. | 249 | 317/162 | 102 | 0.08 % | 0.96 % | 9.36 % | 2.00 | |
| Fredun Pharmaceuticals Ltd | 2,287 Cr. | 1,387 | 1,600/427 | 51.4 | 170 | 0.02 % | 21.5 % | 15.8 % | 10.0 |
| Beta Drugs Ltd | 2,262 Cr. | 2,040 | 2,808/990 | 49.6 | 241 | 0.00 % | 19.2 % | 18.8 % | 10.0 |
| Panacea Biotec Ltd | 2,246 Cr. | 366 | 648/292 | 136 | 0.00 % | 2.43 % | 2.42 % | 1.00 | |
| RPG Life Sciences Ltd | 4,911 Cr. | 2,955 | 3,130/1,731 | 42.1 | 366 | 0.81 % | 25.7 % | 19.3 % | 8.00 |
| Venus Remedies Ltd | 2,176 Cr. | 1,629 | 2,044/424 | 18.7 | 497 | 0.61 % | 20.7 % | 15.6 % | 10.0 |
| Syncom Formulations (India) Ltd | 2,086 Cr. | 22.2 | 23.4/10.2 | 24.6 | 4.39 | 0.45 % | 24.8 % | 17.6 % | 1.00 |
| Gujarat Themis Biosyn Ltd | 5,170 Cr. | 398 | 479/225 | 106 | 26.4 | 0.17 % | 18.1 % | 17.4 % | 1.00 |
| Hester Biosciences Ltd | 1,826 Cr. | 2,147 | 2,684/1,239 | 34.4 | 423 | 0.51 % | 15.2 % | 15.9 % | 10.0 |
| Jagsonpal Pharmaceuticals Ltd | 1,586 Cr. | 241 | 265/155 | 33.8 | 41.2 | 1.66 % | 22.7 % | 17.3 % | 2.00 |
| FDC Ltd | 5,593 Cr. | 344 | 476/313 | 18.2 | 153 | 1.46 % | 15.4 % | 11.2 % | 1.00 |
| Amrutanjan Health Care Ltd | 1,465 Cr. | 507 | 760/476 | 23.6 | 128 | 0.97 % | 24.8 % | 18.4 % | 1.00 |
| TTK Healthcare Ltd | 1,433 Cr. | 1,014 | 1,250/735 | 18.7 | 789 | 0.99 % | 8.04 % | 6.30 % | 10.0 |
| Fermenta Biotech Ltd | 1,411 Cr. | 479 | 580/249 | 25.8 | 138 | 0.78 % | 20.6 % | 16.4 % | 5.00 |
| Kopran Ltd | 1,342 Cr. | 278 | 294/107 | 53.7 | 110 | 1.08 % | 6.65 % | 4.91 % | 10.0 |
| IOL Chemicals & Pharmaceuticals Ltd | 5,760 Cr. | 196 | 219/67.1 | 32.6 | 61.3 | 0.51 % | 11.3 % | 8.42 % | 2.00 |
| Lincoln Pharmaceuticals Ltd | 1,167 Cr. | 582 | 770/440 | 12.1 | 378 | 0.31 % | 16.3 % | 12.3 % | 10.0 |
| Themis Medicare Ltd | 1,075 Cr. | 117 | 147/65.0 | 43.3 | 0.43 % | 2.74 % | 0.41 % | 1.00 | |
| Orchid Pharma Ltd | 6,129 Cr. | 1,023 | 1,144/471 | 339 | 300 | 0.00 % | 1.86 % | 1.49 % | 10.0 |
| Anuh Pharma Ltd | 898 Cr. | 89.5 | 99.5/66.7 | 20.3 | 35.1 | 1.68 % | 14.9 % | 10.7 % | 5.00 |
| Bafna Pharmaceuticals Ltd | 831 Cr. | 357 | 363/94.8 | 107 | 40.6 | 0.00 % | 11.9 % | 12.3 % | 10.0 |
| Wanbury Ltd | 778 Cr. | 222 | 360/162 | 18.1 | 18.1 | 0.00 % | 36.6 % | 76.5 % | 10.0 |
| Kilitch Drugs (India) Ltd | 761 Cr. | 217 | 234/117 | 25.3 | 80.0 | 0.00 % | 13.4 % | 10.6 % | 10.0 |
| Albert David Ltd | 485 Cr. | 847 | 932/580 | 21.5 | 686 | 0.59 % | 0.82 % | 0.44 % | 10.0 |
| Morepen Laboratories Ltd | 6,611 Cr. | 121 | 127/33.0 | 56.3 | 22.8 | 0.17 % | 8.05 % | 5.33 % | 2.00 |
| SMS Lifesciences India Ltd | 357 Cr. | 1,197 | 1,680/956 | 20.6 | 650 | 0.13 % | 11.8 % | 10.8 % | 10.0 |
| Aarey Drugs & Pharmaceuticals Ltd | 309 Cr. | 99.5 | 104/50.3 | 74.0 | 53.0 | 0.00 % | 5.58 % | 2.75 % | 10.0 |
| Lyka Labs Ltd | 304 Cr. | 84.1 | 105/44.1 | 25.9 | 0.00 % | 5.98 % | 10.2 % | 10.0 | |
| BDH Industries Ltd | 292 Cr. | 507 | 610/340 | 24.9 | 134 | 0.99 % | 20.5 % | 14.8 % | 10.0 |
| Gennex Laboratories Ltd | 242 Cr. | 9.98 | 17.2/7.05 | 12.9 | 9.16 | 0.00 % | 11.8 % | 10.5 % | 1.00 |
| Everest Organics Ltd | 215 Cr. | 216 | 536/197 | 40.9 | 77.7 | 0.00 % | 12.0 % | 7.63 % | 10.0 |
| Nectar Lifescience Ltd | 210 Cr. | 10.7 | 22.5/9.20 | 30.0 | 0.00 % | 0.05 % | 31.3 % | 1.00 | |
| Ambalal Sarabhai Enterprises Ltd | 203 Cr. | 26.5 | 42.0/23.1 | 11.4 | 19.2 | 0.00 % | 9.12 % | 6.25 % | 10.0 |
| Coral Laboratories Ltd | 195 Cr. | 546 | 679/360 | 10.3 | 585 | 0.37 % | 11.0 % | 7.79 % | 10.0 |
| Bal Pharma Ltd | 167 Cr. | 105 | 125/59.7 | 23.1 | 51.6 | 1.15 % | 9.69 % | 7.87 % | 10.0 |
| Brooks Laboratories Ltd | 167 Cr. | 56.6 | 144/36.3 | 12.6 | 41.6 | 0.00 % | 21.2 % | 22.0 % | 10.0 |
| Par Drugs & Chemicals Ltd | 160 Cr. | 130 | 180/78.0 | 11.0 | 91.0 | 0.00 % | 14.6 % | 9.95 % | 10.0 |
| Achyut Healthcare Ltd | 156 Cr. | 6.46 | 10.0/4.70 | 487 | 1.45 | 0.00 % | 1.18 % | 0.96 % | 1.00 |
| Auro Laboratories Ltd | 147 Cr. | 235 | 317/159 | 30.6 | 74.4 | 0.00 % | 9.52 % | 8.49 % | 10.0 |
| Godavari Drugs Ltd | 138 Cr. | 126 | 135/69.7 | 35.4 | 74.8 | 0.00 % | 6.55 % | 6.14 % | 10.0 |
| Gujarat Inject (Kerala) Ltd | 137 Cr. | 9.35 | 14.3/1.96 | 45.7 | 0.81 | 0.00 % | 22.9 % | 16.6 % | 1.00 |
| Lactose (India) Ltd | 134 Cr. | 106 | 136/76.0 | 19.3 | 51.5 | 0.00 % | 11.3 % | 9.81 % | 10.0 |
| Alpa Laboratories Ltd | 124 Cr. | 59.2 | 99.8/46.0 | 28.4 | 93.4 | 0.00 % | 8.91 % | 7.90 % | 10.0 |
| Krebs Biochemicals & Industries Ltd | 120 Cr. | 57.6 | 76.8/38.3 | 75.5 | 0.00 % | 15.4 % | % | 10.0 | |
| Vaishali Pharma Ltd | 111 Cr. | 8.50 | 12.0/4.75 | 26.2 | 5.29 | 0.00 % | 8.93 % | 6.02 % | 2.00 |
| Concord Drugs Ltd | 104 Cr. | 78.6 | 92.5/61.0 | 50.7 | 36.8 | 0.00 % | 5.19 % | 2.52 % | 10.0 |
| Pharmaids Pharmaceuticals Ltd | 104 Cr. | 29.6 | 66.0/25.6 | 13.5 | 0.00 % | 18.5 % | 26.5 % | 10.0 | |
| Denis Chem Lab Ltd | 95.4 Cr. | 68.7 | 97.4/56.1 | 12.0 | 66.0 | 3.64 % | 14.0 % | 9.52 % | 10.0 |
| Ind-Swift Ltd | 85.4 Cr. | 15.8 | / | 10.9 | 74.2 | 0.00 % | 11.9 % | % | 2.00 |
| Fervent Synergies Ltd | 76.4 Cr. | 15.3 | 26.0/13.0 | 21.0 | 11.4 | 0.00 % | 7.21 % | 7.22 % | 10.0 |
| Cian Healthcare Ltd | 57.7 Cr. | 23.1 | 23.1/4.72 | 3.42 | 0.00 % | 15.1 % | 49.2 % | 10.0 | |
| ANG Lifesciences India Ltd | 53.6 Cr. | 41.1 | 49.7/17.6 | 47.6 | 0.00 % | 0.95 % | 7.33 % | 10.0 | |
| Biofil Chemicals & Pharmaceuticals Ltd | 50.8 Cr. | 31.5 | 46.8/25.6 | 106 | 13.2 | 0.00 % | 2.97 % | 2.83 % | 10.0 |
| Bharat Immunological & Biological Corporation Ltd | 49.0 Cr. | 11.4 | 22.6/11.2 | 18.2 | 0.00 % | 9.27 % | 17.7 % | 10.0 | |
| Mangalam Drugs and Organics Ltd | 48.8 Cr. | 30.9 | 77.9/22.7 | 65.3 | 0.00 % | 14.0 % | 34.8 % | 10.0 | |
| Vivimed Labs Ltd | 48.1 Cr. | 5.66 | 29.4/4.75 | 25.4 | 0.00 % | 65.2 % | % | 2.00 | |
| Bacil Pharma Ltd | 39.5 Cr. | 27.5 | 61.8/10.6 | 60.7 | 17.3 | 0.00 % | 3.93 % | 6.21 % | 10.0 |
| Murae Organisor Ltd | 38.8 Cr. | 0.19 | 0.60/0.19 | 2.56 | 1.02 | 0.00 % | 4.20 % | 5.69 % | 1.00 |
| Chandra Bhagat Pharma Ltd | 37.3 Cr. | 49.4 | 53.0/29.7 | 12.2 | 43.9 | 0.00 % | 12.1 % | 9.67 % | 10.0 |
| Gujarat Terce Laboratories Ltd | 30.4 Cr. | 39.0 | 59.8/29.0 | 13.7 | 12.5 | 0.00 % | 39.2 % | 30.2 % | 10.0 |
| Checkpoint Trends Ltd | 18.0 Cr. | 32.9 | 144/28.4 | 14.6 | 42.5 | 0.00 % | 15.0 % | 12.7 % | 10.0 |
| Ortin Laboratories Ltd | 16.4 Cr. | 20.1 | 26.4/16.2 | 3.47 | 0.00 % | 60.2 % | 118 % | 10.0 | |
| Desh Rakshak Aushdhalaya Ltd | 15.3 Cr. | 26.9 | 59.6/22.4 | 27.9 | 23.3 | 0.00 % | 7.50 % | 5.59 % | 10.0 |
| Beryl Drugs Ltd | 12.1 Cr. | 23.9 | 27.6/15.9 | 19.6 | 19.5 | 0.00 % | 7.25 % | 4.34 % | 10.0 |
| Dipna Pharmachem Ltd | 12.0 Cr. | 4.57 | 25.0/3.90 | 4.57 | 23.7 | 0.00 % | 7.64 % | 5.22 % | 10.0 |
| Chemo Pharma Laboratories Ltd | 11.6 Cr. | 77.4 | 153/70.0 | 8.60 | 0.00 % | 0.28 % | 0.28 % | 10.0 | |
| Colinz Laboratories Ltd | 9.41 Cr. | 74.7 | 87.9/36.1 | 18.8 | 39.9 | 0.00 % | 7.20 % | 5.23 % | 10.0 |
| Adline Chem Lab Ltd | 8.80 Cr. | 15.0 | 17.1/7.60 | 3.03 | 0.00 % | 1,267 % | % | 10.0 | |
| Ganga Pharmaceuticals Ltd | 7.39 Cr. | 12.5 | 14.0/9.35 | 73.9 | 14.1 | 0.00 % | 2.90 % | 1.30 % | 10.0 |
| Brawn Biotech Ltd | 6.42 Cr. | 21.4 | 24.4/17.7 | 7.55 | 14.5 | 0.00 % | 0.00 % | 24.4 % | 10.0 |
| Decipher Labs Ltd | 6.06 Cr. | 6.00 | 11.0/5.00 | 20.5 | 0.00 % | 16.7 % | 14.2 % | 10.0 | |
| Amerise Biosciences Ltd | 5.35 Cr. | 0.81 | 1.03/0.50 | 0.82 | 0.00 % | 0.37 % | 0.37 % | 1.00 | |
| Fabino Enterprises Ltd | 4.27 Cr. | 20.3 | 27.0/13.0 | 18.7 | 0.00 % | 6.22 % | 8.76 % | 10.0 | |
| MPS Pharmaa Ltd | 3.98 Cr. | 2.08 | 2.08/1.57 | 0.04 | 0.00 % | 13.1 % | 177 % | 10.0 | |
| Evoq Remedies Ltd | 3.81 Cr. | 1.53 | 6.11/1.35 | 17.8 | 0.00 % | 0.56 % | 0.54 % | 10.0 | |
| Sanofi India Ltd | 7,148 Cr. | 3,104 | 4,898/3,049 | 20.8 | 359 | 2.42 % | 57.5 % | 43.0 % | 10.0 |
| Entero Healthcare Solutions Ltd | 7,789 Cr. | 1,790 | 1,920/944 | 60.4 | 388 | 0.00 % | 10.5 % | 6.94 % | 10.0 |
| Bliss GVS Pharma Ltd | 7,793 Cr. | 738 | 745/118 | 56.6 | 113 | 0.20 % | 16.9 % | 11.8 % | 1.00 |
| Aarti Pharmalabs Ltd | 8,293 Cr. | 914 | 962/584 | 38.5 | 234 | 0.38 % | 10.7 % | 8.59 % | 5.00 |
| Sequent Scientific Ltd | 8,768 Cr. | 201 | 260/111 | 203 | 32.2 | 0.00 % | 8.47 % | 3.21 % | 2.00 |
| Procter & Gamble Health Ltd | 8,949 Cr. | 5,400 | 6,975/4,700 | 26.9 | 316 | 2.87 % | 83.9 % | 61.9 % | 10.0 |
| Suven Life Sciences Ltd | 9,090 Cr. | 322 | 403/124 | 22.4 | 0.00 % | 79.5 % | 81.5 % | 1.00 | |
| Blue Jet Healthcare Ltd | 10,551 Cr. | 557 | 693/325 | 44.9 | 78.4 | 0.22 % | 26.1 % | 19.4 % | 2.00 |
| Concord Biotech Ltd | 14,564 Cr. | 1,393 | 1,668/987 | 51.2 | 193 | 0.54 % | 17.4 % | 12.6 % | 1.00 |
| Natco Pharma Ltd | 14,827 Cr. | 829 | 1,227/789 | 13.0 | 515 | 0.60 % | 17.4 % | 17.1 % | 2.00 |
| Marksans Pharma Ltd | 15,027 Cr. | 332 | 351/155 | 29.1 | 66.7 | 0.27 % | 18.8 % | 15.2 % | 1.00 |
| Astrazeneca Pharma India Ltd | 15,669 Cr. | 6,280 | 9,850/6,262 | 90.3 | 349 | 0.57 % | 29.3 % | 23.3 % | 2.00 |
| Alembic Pharmaceuticals Ltd | 16,796 Cr. | 854 | 998/635 | 22.5 | 289 | 1.40 % | 12.6 % | 13.4 % | 2.00 |
| Jubilant Pharmova Ltd | 16,858 Cr. | 1,060 | 1,185/784 | 43.4 | 445 | 0.47 % | 8.99 % | 6.53 % | 1.00 |
| ERIS Lifesciences Ltd | 17,128 Cr. | 1,236 | 1,740/1,200 | 26.1 | 282 | 0.58 % | 14.1 % | 18.7 % | 1.00 |
| Cohance Lifesciences Ltd | 17,351 Cr. | 453 | 918/267 | 161 | 102 | 0.00 % | 5.81 % | 4.89 % | 1.00 |
| Pfizer Ltd | 18,132 Cr. | 3,968 | 5,578/3,925 | 23.6 | 919 | 1.89 % | 24.1 % | 18.0 % | 10.0 |
| Shilpa Medicare Ltd | 20,072 Cr. | 1,025 | 1,076/260 | 70.6 | 132 | 0.06 % | 10.9 % | 8.99 % | 1.00 |
| Caplin Point Laboratories Ltd | 21,688 Cr. | 2,854 | 2,991/1,500 | 32.6 | 443 | 0.28 % | 24.2 % | 20.9 % | 2.00 |
| Granules India Ltd | 23,153 Cr. | 851 | 924/511 | 35.6 | 205 | 0.21 % | 15.5 % | 13.8 % | 1.00 |
| Acutaas Chemicals Ltd | 26,321 Cr. | 3,214 | 3,740/1,290 | 68.2 | 202 | 0.08 % | 31.6 % | 24.0 % | 5.00 |
| Neuland Laboratories Ltd | 27,490 Cr. | 21,440 | 24,235/11,500 | 55.2 | 1,461 | 0.16 % | 26.5 % | 21.2 % | 10.0 |
| Wockhardt Ltd | 35,534 Cr. | 2,188 | 2,422/1,087 | 89.1 | 304 | 0.00 % | 7.55 % | 6.11 % | 5.00 |
| J B Chemicals & Pharmaceuticals Ltd | 38,677 Cr. | 2,409 | 2,526/1,603 | 53.8 | 259 | 0.91 % | 25.4 % | 18.9 % | 1.00 |
| Ajanta Pharma Ltd | 44,039 Cr. | 3,525 | 3,797/2,330 | 38.8 | 362 | 0.91 % | 34.5 % | 27.1 % | 2.00 |
| Gland Pharma Ltd | 47,817 Cr. | 2,896 | 3,042/1,574 | 33.8 | 656 | 0.69 % | 17.4 % | 12.8 % | 1.00 |
| Ipca Laboratories Ltd | 48,726 Cr. | 1,919 | 2,039/1,252 | 35.5 | 318 | 0.31 % | 17.0 % | 15.7 % | 1.00 |
| Glaxosmithkline Pharmaceuticals Ltd | 49,047 Cr. | 2,896 | 3,121/2,088 | 46.6 | 134 | 1.97 % | 61.4 % | 45.6 % | 10.0 |
| Abbott India Ltd | 56,863 Cr. | 26,740 | 30,655/25,135 | 35.2 | 2,247 | 1.96 % | 44.8 % | 34.4 % | 10.0 |
| Biocon Ltd | 61,282 Cr. | 375 | 447/337 | 84.3 | 210 | 0.13 % | 3.61 % | 1.40 % | 5.00 |
| Alkem Laboratories Ltd | 61,922 Cr. | 5,175 | 5,934/5,051 | 27.2 | 1,156 | 1.02 % | 21.2 % | 18.9 % | 2.00 |
| Glenmark Life Sciences Ltd | 65,554 Cr. | 2,326 | 2,538/1,793 | 21.0 | 372 | 0.21 % | 39.8 % | 23.6 % | 1.00 |
| Glenmark Pharmaceuticals Ltd | 65,554 Cr. | 2,326 | 2,538/1,793 | 21.0 | 372 | 0.21 % | 39.8 % | 23.6 % | 1.00 |
| Lupin Ltd | 94,383 Cr. | 2,062 | 2,530/1,900 | 15.8 | 491 | 0.87 % | 29.9 % | 28.7 % | 2.00 |
| Aurobindo Pharma Ltd | 97,710 Cr. | 1,698 | 1,740/1,066 | 25.8 | 652 | 0.24 % | 12.9 % | 10.1 % | 1.00 |
| Mankind Pharma Ltd | 1,00,579 Cr. | 2,436 | 2,642/1,910 | 44.5 | 397 | 0.04 % | 13.7 % | 13.8 % | 1.00 |
| Dr Reddys Laboratories Ltd | 1,01,762 Cr. | 1,221 | 1,415/1,080 | 31.6 | 454 | 0.66 % | 13.0 % | 11.2 % | 1.00 |
| Laurus Labs Ltd | 1,08,966 Cr. | 2,011 | 2,055/826 | 125 | 97.3 | 0.10 % | 16.0 % | 15.2 % | 2.00 |
| Cipla Ltd | 1,11,985 Cr. | 1,384 | 1,673/1,166 | 31.3 | 426 | 0.94 % | 15.5 % | 11.6 % | 2.00 |
| Torrent Pharmaceuticals Ltd | 1,85,331 Cr. | 4,869 | 5,250/3,480 | 83.1 | 248 | 0.78 % | 15.2 % | 27.4 % | 5.00 |
| Industry Average | 17,774.69 Cr | 1,258.96 | 55.96 | 211.60 | 0.38% | 26.16% | 16.59% | 6.06 |
How to use this peer comparison
Start with similar company sizes, then compare P/E with ROCE and ROE. A lower P/E alone does not establish better value. Negative earnings, unusual items, debt and different reporting dates can make ratios unsuitable for direct comparison.
The company list is ordered by market-cap proximity to Ind-Swift Laboratories Ltd, with P/E as a secondary comparison. The industry-average row uses available stored values across the industry, which can include companies beyond the rows shown. Missing values are not zero.
Open each company report for financial statements and its cited sources. Industry classifications indicate a research peer group, not a verified list of direct commercial competitors.
Read the full Ind-Swift Laboratories Ltd analysis · Explore all Pharmaceuticals stocks